Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy

Urology

Volumn 55, Issue 6, 2000, Pages 934-938

  Krainer, Michael ^a   Wolf, Hermann M ^a   Wiltschke, Christoph ^a   Wilfing, Astrid ^a   Kaider, Alexandra ^a   Kratzik, Christian ^a   Eibl, Martha M ^a   Zielinski, Christoph C ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CONCANAVALIN A; ETOPOSIDE; INTERLEUKIN 2 RECEPTOR; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN;

ARTICLE; CELLULAR IMMUNITY; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; GERM CELL TUMOR; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; TESTIS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; CONCANAVALIN A; ETOPOSIDE; GERMINOMA; HUMANS; IMMUNITY, CELLULAR; LECTINS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; RECEPTORS, INTERLEUKIN-2; TESTICULAR NEOPLASMS;

EID: 0034067957     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00524-0     Document Type: Article

References (15)

1. Einhorn L. Testicular cancer as a model for a curable neoplasm. Cancer Res. 41:1981;3275-3280.
2. Peckham M.J., Barrett A., Husband J.E., et al. Orchidectomy alone in testicular stage I nonseminomateous germ cell tumors. Lancet. 2:1982;678-680.
3. Williams D., Stablein D.M., Einhorn L.H., et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 317:1987;1433-1438.
4. Krainer M., Wolf H., Michl I., et al. Natural killer cell activity in long-term survivors of testicular cancer influence of cytostatic therapy and initial stage of disease . Cancer. 75:1995;539-544.
5. Tichatschek E., Zielinski C.C., Muller C., et al. Long term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother. 27:1988;278-282.
6. Hanna N., Burton R.C. Definitive evidence that natural killer cells inhibit experimental tumor metastasis in vivo. J Immunol. 127:1986;1754-1758.
7. Mackall C.L., Fleisher T.A., Brown M.R., et al. Age, thymopoiesis, and CD4+ lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 332:1995;143-149.
8. Wiltschke C., Krainer M., Budinsky A.C., et al. Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer a prospective longitudinal study . Br J Cancer. 71:1995;1292-1296.
9. Zielinski C.C., Müller C., Tichatschek E., et al. Decreased production of soluble interleukin 2 receptor by phytohaemagglutinin-stimulated peripheral blood mononuclear cells in patients with breast cancer after adjuvant therapy. Br J Cancer. 60:1989;712-714.
10. Kirk RE Experimental Design, 2nd ed . 1982;Brooks/Cole Publishing, Belmont, California.
11. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 6:1979;65-70.
12. Liu C.C., Young L.H.Y., Young J.D.E. Lymphocyte-mediated cytolysis and disease. N Engl J Med. 335:1996;577-580.
13. Rosenberg S.A., Packard B.S., Aebersold P.M., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma a preliminary report . N Engl J Med. 319:1988;1676-1680.
14. Kradin R.L., Kurnick J.T., Lazarus D.S., et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1:1989;577-580.
15. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:1999;281-287.